Bevacizumab with Paclitaxel and Carboplatin as Neo Adjuvant Chemotherapy for Stage 4 Ovarian Cancer- Case Report

Ovarian cancer, the fifth most common neoplasia in women, presents challenges in diagnosis and treatment, often resulting in poor prognosis due to advanced stage at diagnosis and limited treatment options. Platinum-based chemotherapy and surgery have been the mainstay treatments, but efforts to improve outcomes with additional cytotoxic drugs have yielded mixed results. Angiogenesis plays a crucial role in tumor growth and metastasis, leading to the investigation of bevacizumab, a monoclonal antibody targeting vascular endothelial growth factor (VEGF). Clinical trials have demonstrated its efficacy in delaying disease progression in ovarian cancer. This case report illustrates the successful use of neoadjuvant chemotherapy followed by surgery and maintenance therapy with bevacizumab and olaparib in a patient with advanced ovarian cancer, highlighting the potential benefits of this treatment approach in improving survival outcomes.